Hans-Joachim Anders @hjanders_hans Twitter profile

Last Seen Profiles

@HikariJima

@penyukastw21

@xv_yuika

@ya71742

@domingoKITAP

@LatittaLove

@Pedrolo45585045

@lovely__human

@bokeplokalmalam

@KMenrui

@mercuryinretro1

@LynnLoera

@SilverburgSSB

@juju_1718

@lemonbabee_

@celiahzg

@Hanikeeperdrakt

@ThickDFreak

@616Ahe421

@PahlinUrat

@FarrahBritt

@e_hassn2

@JgfLrC36evlPfMd

@tonyhilbert295

@jae_yi_0100

@MeiShui43891

@erica_big_boobs

@Immen82

@Flowski2x

@alexandermackie

@kesingidilmeli

@tydrago

@EviatarBarak

@CresswellL53274

@llotuszz

@ameliaashill13

Hans-Joachim Anders

@hjanders_hans

2 years

Fresh from the press in @NatRevImmunol The 5 types of glomerulonephritis that connect pathogenesis with immunotherapy thanks to @PRomagnani @KitchingLab and Nelson Leung from Mayo

6

97

283

Hans-Joachim Anders

@hjanders_hans

3 months

Now online in @NDTsocial Hyponatremia - Treatment standard 2024 🥸 A gradual correction and clinical evaluation is preferable over the rapid normalization of serum sodium towards the laboratory reference ranges. ▶️

3

80

199

Hans-Joachim Anders

@hjanders_hans

4 years

Cardiorenal Syndrome Type 3 @NEJM

0

80

171

Hans-Joachim Anders

@hjanders_hans

16 days

Dialysis for Chronic Kidney Failure: A Review | Renal Replacement | JAMA | JAMA Network

Dialysis for Chronic Kidney Failure

This narrative review explores the use of maintenance hemodialysis and peritoneal dialysis in the treatment of dialysis-dependent chronic kidney failure, including diagnosis, pathophysiology, and...

jamanetwork.com

2

35

167

Hans-Joachim Anders

@hjanders_hans

24 days

Our latest review just went online in @NatRevRheumatol #Lupus nephritis-related chronic CKD Check out all things to do beyond prescribing immunosuppressants to improve kidney outcomes (together with your nephrologist) Here is a free view only link

2

52

155

Hans-Joachim Anders

@hjanders_hans

3 months

Now open access in @NDTsocial Antibody-mediated podocytopathies: a disease entity that implies immunotherapy 🧐A novel disease concept beyond MCD/FSGS lesion patterns discussed by the Immunonephrology Working Group of @ERAkidney ▶️

3

64

155

Hans-Joachim Anders

@hjanders_hans

4 years

All you need to know about ANCA vasculitis. Epidemiology-Clinical Presentation- Pathophysiology, Diagnosis, Biomarkers, Management, QoL, Outlook, @eular_org @ERAEDTA @ISNkidneycare @GlomCon @RELENT_EU @DiseasePrimers

2

65

141

Hans-Joachim Anders

@hjanders_hans

11 months

Now free online in @NDTsocial "ANCA vasculitis Treatment Standard" by @davidjayne2 et al. ▶️ GPA/MPA ▶️ EGPA

1

51

129

Hans-Joachim Anders

@hjanders_hans

8 months

Now open access in @NDTsocial Management of adult patients with podocytopathies - an update from the ERA Immunonephrology Working Group @smirioglu @AKronbichler ▶️

0

51

128

Hans-Joachim Anders

@hjanders_hans

4 years

Our primer on "Lupus nephritis" is now free online during the Springer Nature collection “Rheumatic Disease Awareness Month” until Oct 20. @kidneydoc101 @BradRovin

1

53

119

Hans-Joachim Anders

@hjanders_hans

1 year

The new IF of the #kidney journals

3

28

121

Hans-Joachim Anders

@hjanders_hans

1 year

Lupus nephritis treatment algorithm according to EULAR 2023

0

52

120

Hans-Joachim Anders

@hjanders_hans

2 years

New impact factors of kidney journals found on Clarivate Journal Citation Reports 🤓😀👏🎉

8

23

118

Hans-Joachim Anders

@hjanders_hans

1 year

🥳Long journey from writing (small parts) to holding the heavy book in the hands. A lot of knowledge and beautiful images...enjoy thanks @AgnesFogo

1

15

111

Hans-Joachim Anders

@hjanders_hans

2 months

Now online at @NDTsocial @HerrmannMd Immune checkpoint inhibitor-associated nephritis - treatment standard 🧐A subset of patients will require additional steroid-sparing therapies for corticosteroid-dependent or refractory ICI-AKI. ▶️

1

55

109

Hans-Joachim Anders

@hjanders_hans

1 year

Now in @JASN_News . Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Contr…

Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Contro...

Experiments in mice suggest that triple RAS/SGLT2/MR blockade may substantially improve renal outcomes in Alport syndrome and possibly other progressive CKDs because of synergistic effects on the...

pubmed.ncbi.nlm.nih.gov

5

32

103

Hans-Joachim Anders

@hjanders_hans

1 year

Chronic kidney disease is coming to the stage. Check this special edition of Nature (Nature)

Chronic kidney disease

Every 30 minutes, our kidneys filter all the blood in the body.

www.nature.com

0

38

102

Hans-Joachim Anders

@hjanders_hans

1 year

IgAN, MN, SLE, ANCA-GN,... all seem different GNs but all develop from same immune system. Only AGs differ ⏩location of 🔥. But we don`t target AG! We target always the same immune system. Tx differs only by level of autoimmune activity ⏩ basket RCTs

2

39

100

Hans-Joachim Anders

@hjanders_hans

3 years

How the ratio of kidney workload per no. of nephrons determines healthy kidney ageing versus progressive CKD. @valerie_luyckx @PRomagnani @KatherineTuttl8 @PStoneOftheYear @NatRevNeph

0

40

97

Hans-Joachim Anders

@hjanders_hans

4 years

Now open access in Nat Rev Dis Primers "Podocytopathies" An updated view on nephrotic syndromes (MCD, FSGS, SSNS, SRNS, ...). Role of APOL1, global epidemiology, pathomechanisms, diagnostics, QoL, and management. @nephcure

5

50

96

Hans-Joachim Anders

@hjanders_hans

1 year

During his 25 years as a nephrologist, HJA has travelled to many conferences on kidney disease. On his return, his patients often ask him if he has learnt anything relevant to them. For more than two decades, “I had to tell them no”… 🙏 that changed

SGLT2 inhibitors breathe life into kidney-disease care

Nature - Researchers want to expand the use of drugs that protect the hearts and kidneys of people with chronic kidney disease.

www.nature.com

3

26

95

Hans-Joachim Anders

@hjanders_hans

6 months

Now open access in @NDTsocial Editorial by ERA president-elect @torra_roser 👉Kidney disease - the elefant in the room ▶️

0

30

93

Hans-Joachim Anders

@hjanders_hans

1 year

Finally out:

1

32

92

Hans-Joachim Anders

@hjanders_hans

2 years

Finally, some key mechanisms of #AKI depicted by this @NatureNV outline . Read also . @DiseasePrimers

What is acute kidney injury? A visual guide

Nature - Early detection and prompt treatment could prevent long-term health effects of acute kidney injury, a condition that commonly arises while people are in hospital.

www.nature.com

0

37

87

Hans-Joachim Anders

@hjanders_hans

10 months

Now open access in @NDTsocial The new generation of B cell-targeting therapies for the treatment of autoimmune kidney diseases ▶️

0

33

87

Hans-Joachim Anders

@hjanders_hans

24 days

1. episode of #lupus nephritis = irreversible nephron loss, which 🔽kidney functional reserve, e.g., needed for a pregnancy. Result: HTN, proteinuria, preeclampsia rates as kidneys do not stand the ⬆️workload. Same with obesity/DM later in life

1

17

87

Hans-Joachim Anders

@hjanders_hans

20 days

Now open access in the October issue of @NDTsocial @AndrewRuleMD Structural adaptation to hyperfiltration defines CKD versus healthy aging ▶️

1

33

85

Hans-Joachim Anders

@hjanders_hans

1 year

⏩ Check this: Target RR, SGLT2inh, finerenone, chlorthalidone, etc 2023 ESH Guidelines for the management of arterial... : Journal of Hypertension

1

33

79

Hans-Joachim Anders

@hjanders_hans

11 months

Now released by @NDTsocial Anaemia in CKD - treatment standard by Ian MacDougall ⏩

1

30

80

Hans-Joachim Anders

@hjanders_hans

1 year

@NDTsocial Latest GN supplement all free online ▶️New GN classification ▶️Factor Bb predicts IgAN outcomes ▶️All immunomodulatory drugs for kidney disease ▶️Novel complement inhibitors for GN ▶️How to prevent infections in GN ▶️CKD therapy in GN

1

30

77

Hans-Joachim Anders

@hjanders_hans

1 year

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease | NEJM Evidence

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

In the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial, dapagliflozin improved kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) with or withou...

evidence.nejm.org

2

32

76

Hans-Joachim Anders

@hjanders_hans

4 months

Now open access in @NDTsocial A Stain Reclaimed: The Legacy of Drs. Prescott & Brodie by @jrseltzer @VelezNephHepato @rmothy 🧐This stain reduces confusion for both the novice and experienced clinician doing urinary microscopy. ⏩

3

28

72

Hans-Joachim Anders

@hjanders_hans

1 year

The adverse effect of SGLT2 inh not reported in RCTs/metanalysis: Worrisome increases in Hgb levels - now free online in NDT Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to hematology

0

14

70

Hans-Joachim Anders

@hjanders_hans

25 days

Now open access in @NDTsocial SELECT: a 10% reduction in body weight with GLP-1 receptor agonists improves kidney outcomes in overweight and obese patients without diabetes

2

21

71

Hans-Joachim Anders

@hjanders_hans

1 year

Now free online from NATURE

0

14

72

Hans-Joachim Anders

@hjanders_hans

15 days

Happy to see this finally out. The first study able to define the sensitivity and specificity of commercial anti-nephrin Ab by using kidney biopsies as gold standard. Standard Elisas do the job well.

Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant...

Podocytopathies represent a group of glomerular disorders associated with minimal changes (MC) or focal segmental glomerulosclerosis (FSGS) lesion patterns at biopsy and heterogeneous responses to...

www.kidney-international.org

1

18

72

Hans-Joachim Anders

@hjanders_hans

1 year

The NDT editorial on the NEJM CONVINCE study comparing outcomes of HD versus HDF dialysis. Haemodiafiltration for all: are we CONVINCEd?

Haemodiafiltration for all: are we CONVINCEd?

Nearly 4 million people in the world receive life-sustaining kidney replacement therapy, with haemodialysis (HD) accounting for approximately 69% of all tr

academic.oup.com

0

26

69

Hans-Joachim Anders

@hjanders_hans

8 months

Now open access in @NDTsocial CKD screening for better kidney health: Why? Who? How? When? by @KatherineTuttl8 ▶️

3

24

69

Hans-Joachim Anders

@hjanders_hans

1 year

Now open access in @NDTsocial Kidney disease diagnosed with urine analysis only

2

22

67

Hans-Joachim Anders

@hjanders_hans

8 months

Now online in @NDTsocial #SGLT2 inhibition in primary/secondary forms of glomerulonephritis ▶️

0

25

66

Hans-Joachim Anders

@hjanders_hans

1 year

If something in nephrology is too complicated to be explained to medical students, e.g., #glomerulonephritis , it`s likely not yet well understood Read how everyone can understand the GNs: ▶️ @KitchingLab @PRomagnani

Physics In History

@PhysInHistory

1 year

The most important equations in Physics and Mathematics 🧠

228

5K

22K

1

9

65

Hans-Joachim Anders

@hjanders_hans

5 years

60% diagnostic rate with genetic testing in steroid-resistant nephrotic syndrome. Phenocopies as frequent as podocytopathies #SRNS @CJASN @KidneyNews @IPNA_PedNeph @Nephcure

3

31

64

Hans-Joachim Anders

@hjanders_hans

20 days

Now open access in @NDTsocial IV methylprednisolone for nephrotic syndrome with minimal change lesions in adults: a RCT 🧐 Short-term IV MP followed by oral pred may be a better choice for NS patients with MC lesions ▶️

1

21

65

Hans-Joachim Anders

@hjanders_hans

4 months

Now online in @NDTsocial Clinical and histological comparison of IgAN and renal IgAV 🧐 IgAN and IgAV follow distinct courses/require different tx strategies. Oxford classif.&LN-CI can categorize and predicting long-term prognosis in both ▶️

0

18

62

Hans-Joachim Anders

@hjanders_hans

9 months

Now out in @NDTsocial When to use either spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases ▶️

0

19

62

Hans-Joachim Anders

@hjanders_hans

1 year

Association between serum iron markers, iron supplementation, and cardiovascular morbidity in pre-dialysis chronic kidney disease | Nephrology Dialysis Transplantation | Oxford Academic

Association between serum iron markers, iron supplementation and cardiovascular morbidity in...

ABSTRACTBackground. The optimal range of serum iron markers and usefulness of iron supplementation are uncertain in patients with pre-dialysis chronic kidn

academic.oup.com

1

23

60

Hans-Joachim Anders

@hjanders_hans

4 years

New impact factors of #Kidney journals

4

23

61

Hans-Joachim Anders

@hjanders_hans

1 year

Do you know our short author videos of accepted @NDTsocial papers? Here is our latest on SGLT2i in GN Here is the full collection of NDT author videos (free access)

0

17

60

Hans-Joachim Anders

@hjanders_hans

4 years

Kidney update 2020 from @ScienceMagazine with contributions of @KSusztak @PRomagnani @mrins01

2

15

57

Hans-Joachim Anders

@hjanders_hans

1 year

basics of phosphate metabolism

The basics of phosphate metabolism

ABSTRACT. Phosphorus is an essential mineral that is, in the form of inorganic phosphate (Pi), required for building cell membranes, DNA and RNA molecules,

academic.oup.com

0

18

59

Hans-Joachim Anders

@hjanders_hans

3 years

Now online: The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021 @AnnetteBruchfe1 @AKronbichler @KateIsabelle24

The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021

ABSTRACT. In 2019 and 2021, the European League for Rheumatism (EULAR) jointly with the European Renal Association (ERA) and the Kidney Disease: Improving

academic.oup.com

1

25

58

Hans-Joachim Anders

@hjanders_hans

8 months

Now online in @NDTsocial A predictive mortality score in ANCA-associated renal vasculitis ▶️

1

21

56

Hans-Joachim Anders

@hjanders_hans

7 months

Now open access in J Autoimmun Balancing efficacy and safety of complement inhibitors

1

15

55

Hans-Joachim Anders

@hjanders_hans

2 months

Now online in @NDTsocial Anti-C1Q monitoring predicts relapses of #lupus nephritis 🧐High titres of anti-C1qAb at start of therapy and their persistent positivity at 1 year is strongly associated with renal flares. ▶️

2

29

55

Hans-Joachim Anders

@hjanders_hans

1 year

Recovery of Kidney Function After Acute Kidney Disease - a Multi-Cohort Analysis

1

20

55

Hans-Joachim Anders

@hjanders_hans

1 year

Important concepts because low nephron no is a 🔝RF for HTN, proteinuria of any cause, pre-eclampsia, DKD, progression of CKD, AKI/CKD transition etc etc. Nephrons develop by log2 , so most come from the last rounds of branching = last wks of pregnancy @valerie_luyckx

Nature Reviews Nephrology

@NatRevNeph

1 year

Nephrogenesis in the mouse

0

27

87

3

21

53

Hans-Joachim Anders

@hjanders_hans

4 years

Does this compromize the ongoing IgAN trials that do not include SGLT2 inhibition as SOC? Will there really be still a need for immune modulators for IgAN, if dual RAS/SGLT2 inhibition is so potent? #asn2020

4

13

54

Hans-Joachim Anders

@hjanders_hans

5 months

Now free online in @NDTsocial Genetic kidney stones disease in adults Editorial by Bernd Hoppe, et al 🧐New treatment options in rare metabolic diseases are now available ▶️

0

19

53

Hans-Joachim Anders

@hjanders_hans

2 months

Now open access in @NDTsocial Extrarenal manifestations in inherited kidney diseases 🧐The interplay between genetic variants and molecular pathways underscores the importance of exploring the extrarenal aspects of inherited kidney diseases. ▶️

0

19

53

Hans-Joachim Anders

@hjanders_hans

2 years

HTN and CKD are frequently associated and causality HTN->CKD is a popular misconcept. The fact that monogenic forms of HTN do not cause CKD disproves HTN->CKD theory. CKD->HTN ! "Essential" HTN: 1. Urine exam, nephron no?, birth weight?, previous AKI?, etc... 2. Aldo/Renin

Richard J. Glassock

@GlassockJ

2 years

@valerie_luyckx Hypertension as a cause of CKD? Think again, please.

4

3

16

8

53

Hans-Joachim Anders

@hjanders_hans

2 months

Now open access in @NDTsocial Placement of tunneled hemodialysis catheters - interventional standard 🧐Novel developments include catheter placement with ultrasound-guidance or ECG-guidance. ▶️

1

19

53

Hans-Joachim Anders

@hjanders_hans

6 months

Now open access in @NDTsocial Albuminuria predicts #kidney events in IgAN 📢 Lower levels of UACR significantly associated with MAKE (major adverse kidney events) 👉 IgAN is glomerular and a form of CKD. UACR seems to be top for assessment ⏩

4

23

53

Hans-Joachim Anders

@hjanders_hans

4 years

Congrats to @StefanieSteige6 for her mechanistic explanation on the controversy on the role of uric acid in the progression of #CKD . Maybe crystalluria can help to identify pts. that potentially benefit from urate-lowering therapy? No role w/o crystals!

0

14

51

Hans-Joachim Anders

@hjanders_hans

1 year

Would you propose population or risk group screening for #CKD as it is an asymptomatic killer?

CKD is a hidden threat, but the treatment landscape is evolving

Early screening and cardio–renal drug combinations are key to preventing more deaths from chronic kidney disease.

www.nature.com

9

15

52

Hans-Joachim Anders

@hjanders_hans

1 year

Everyone speaks about AKI, few speak about AKD, but many pts develop AKD w/o AKI. AKD +/- AKI has important consequences on mortality and subsequent CKD. Incidence and prognosis of AKI versus AKD among 71,041 inpatients

Incidence and prognosis of acute kidney injury versus acute kidney disease among 71 041 inpatients

ABSTRACTBackground. Acute kidney disease (AKD) defines patients with acute kidney injury (AKI) or subacute loss of kidney function lasting for >7 days.

academic.oup.com

0

18

51

Hans-Joachim Anders

@hjanders_hans

1 month

Now online in @NDTsocial Metabolic Alkalosis Treatment Standard 🧐While metabolic alkalosis is frequently not dangerous, in certain settings, metabolic alkalosis may contribute to mortality and should be aggressively managed ▶️

1

20

51

Hans-Joachim Anders

@hjanders_hans

11 months

Had a rhabdomyolysis case today with eGFR(Cr): 15 ml/min and eGFR(Cys): 60 ml/min !?? Good read and now open access in @NDTsocial ▶️"Diagnostic standard: Assessing GFR" by @PStoneOftheYear , et al.

2

17

49

Hans-Joachim Anders

@hjanders_hans

8 months

Now open access in @NDTsocial Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis ⏩

1

19

48

Hans-Joachim Anders

@hjanders_hans

7 months

Now online in @NDTsocial Eculizumab for pregnancy-related aHUS 😇 Kidney survival data much improved with C5 blockade ▶️

1

16

49

Hans-Joachim Anders

@hjanders_hans

3 years

New data on #Belimumab in #lupusnephritis online in @Kidney_Int by @BradRovin BEL attenuates eGFR decline and the risk for LN flares, the main treatment goals in LN!! Lets get away from #proteinuria in kidney RCTs!!

1

18

48

Hans-Joachim Anders

@hjanders_hans

2 years

Proud to be named a Highly Cited Researcher 2022 by @ClarivateAG . See the full list #HighlyCited2022 Thanks to everyone reading and citing our research!!

10

1

48

Hans-Joachim Anders

@hjanders_hans

4 months

Now open access in @NDTsocial Magnesium Biology 🧐Recently, prebiotic dietary fibers and SGLT2 inhibitors have been proposed as promising new therapeutic pathways to treat hypomagnesemia. ▶️

0

17

48

Hans-Joachim Anders

@hjanders_hans

5 months

Now OA in @NDTsocial Primary immunodeficiency (PID) as a cause of immune-mediated kidney diseases 👉PIDs can cause autoimmunity 👉largely neglected in nephrology 👉many possibilities for research 👉PID as cause for infectious complications ▶️

1

20

46

Hans-Joachim Anders

@hjanders_hans

1 year

Now open access in @NDTsocial The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases @AKronbichler @odlerb

0

16

47

Hans-Joachim Anders

@hjanders_hans

5 years

Every patient with #lupusnephritis is a CKD pt. With every LN episode she/he looses nephrons (just as in an AKI episode), Nephron loss = shortening of #kidney life span! Thus, let a pt. with LN NEVER have a 2. LN episode, AKI, drug tox, etc. Check out at

1

26

45

Hans-Joachim Anders

@hjanders_hans

5 months

Now online in @NDTsocial Prophylactic treatment of FSGS recurrence in pts who relapsed in a previous kidney graft 🧐Better no prophylactic treatment in pts receiving a 2nd graft after recurrent FSGS in a previous graft ⏩

1

13

46

Hans-Joachim Anders

@hjanders_hans

7 months

Now open access in @NDTsocial Cardio-renoprotective effects of SGLT2 inhibitors—the role of anaemia correction 😇 more erythropoiesis and hemoconcentration ⏩

0

14

46

Hans-Joachim Anders

@hjanders_hans

1 year

Proximal or distal diuretic to add to loop diuretic for decongestion in heart failure?

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics

AbstractBackground and Aims. To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like

academic.oup.com

0

13

45

Hans-Joachim Anders

@hjanders_hans

8 months

Now open access in @NDTsocial Membranous Nephropathy Treatment Standard ▶️

1

17

45

Hans-Joachim Anders

@hjanders_hans

2 years

1. Most drugs for GN act outside the kidney (spleen, lymph nodes, bone marrow) 2. Long pipeline of drugs for 3 of the 5 groups of GN that connect immunopathogenesis + immunotherapy Now in @NatRevImmunol @KitchingLab @PRomagnani , Nelson Leung Free online:

2

16

45

Hans-Joachim Anders

@hjanders_hans

1 year

Pregnancy-related hyperfiltration is a kidney stress test and those with insufficient reserve to adapt to the increased workload develop HTN and proteinuria like everyone else that exceeds reserve (DM, obesity, low nephron no).

Prof Liz Lightstone PhD FRCP FISN 🇬🇧🇮🇱🇺🇦🇵🇸

@kidneydoc101

1 year

@valerie_luyckx @KatherineTuttl8 @hjanders_hans @PStoneOftheYear @elliotktannor #pregnancy ?!!

1

0

6

1

10

44

Hans-Joachim Anders

@hjanders_hans

4 months

Now online in @NDTsocial A novel approach to induce early remission in high-risk primary membranous nephropathy 👉A combination of RTX, IVCYC, and steroids is effective and safe in high-risk pts ▶️

1

15

43

Hans-Joachim Anders

@hjanders_hans

3 months

Now online in @NDTsocial Biology of the proximal tubule in body homeostasis and kidney disease 🧐The PT is critical for understanding disease phenotypes, their systemic complications and for developing new therapeutic strategies ▶️

0

11

44

Hans-Joachim Anders

@hjanders_hans

6 years

Podocyte-progenitor feedback mechanism inhibiting intrinsic capacity of podocyte regeneration identified! Novel target to stimulate podocyte regeneration and reduce proteinuria in glomerular disease @Kidney_int @ISNkidneycare @PRomagnani

0

22

43

Hans-Joachim Anders

@hjanders_hans

5 years

Fresh from the press: "Lupus nephritis" in Nature Reviews Disease Primers @kidneydoc101 @LupusOrg @LupusInitiative

2

21

42

Hans-Joachim Anders

@hjanders_hans

3 years

End of #2021 token. Just received a copy of this book to which we had the honour to contribute a chapter on renal hemodynamics and the RAS together with @PepaSolerR @MotrapuManga . Thanks @edgarvlermamd and crew. Note that the book title avoids DN/DKD!!

2

4

42

Hans-Joachim Anders

@hjanders_hans

8 months

Now open access in @NDTsocial 😬Weight loss with GLP1- and dual-receptor agonists affect both SCr and Cys-based eGFR formulas suggesting fake kidney function improvements 📢One possible solution: remove body surface correction ⏩

1

16

43

Hans-Joachim Anders

@hjanders_hans

3 years

Important milestone in nephrology. Finally, we can treat hemodynamic and metabolic overload of the remaining nephrons, the major drivers of CKD progression 👍

Alfonso Valle

@ValleAlfonso

3 years

📰 #Dapagliflozin approved in the 🇪🇺 @EMA_News for the treatment of chronic kidney disease in patients with and without type-2 diabetes 👉 Approval based on unprecedented #DAPA -CKD @secardiologia @SENefrologia @CardioRenalSEC 📌

5

76

155

0

13

43

Hans-Joachim Anders

@hjanders_hans

3 months

Now online in @NDTsocial Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection 🧐 From CAR-T cells to CHAR-T cells in order to target alloreactive ab-producing immune cells in the recipient ▶️

0

12

42

Hans-Joachim Anders

@hjanders_hans

3 years

Now out in @NatRevNeph : Nephron overload as a therapeutic target to maximize kidney lifespan. Why #SGLT2 inhibitors work in CKD, and...and...and. @valerie_luyckx @PRomagnani @PStoneOftheYear @KatherineTuttl8

0

16

41

Hans-Joachim Anders

@hjanders_hans

1 year

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) | Novartis

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly...

www.novartis.com

1

10

42

Hans-Joachim Anders

@hjanders_hans

2 years

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) - The Lancet. Also check this:

0

15

42

Hans-Joachim Anders

@hjanders_hans

1 year

Now free online in @FrontImmunol Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes account for organ injury, regeneration or atrophy @buschraml @PRomagnani

0

11

42

Hans-Joachim Anders

@hjanders_hans

1 year

One of the first new NDT treatment Standards, the new clinical guidance format of @NDTsocial from @ERAkidney

James Gleeson

@_JamesGleeson

1 year

Delighted to share our state-of-the-art review on treatment of IgAN in @NDTsocial . Honoured to work on this with @IgAN_JBarratt and @MichelleOShaug3 . Exciting times for IgAN therapeutics!

4

64

165

0

15

42

Hans-Joachim Anders

@hjanders_hans

5 years

Good to remind (and teach...). Interferences in the different methods to measure SCr.

0

15

42

Hans-Joachim Anders

@hjanders_hans

5 years

These results have important implications! Once SCr is elevated (CKD3 or more) it's tooo late (>65% of nephrons lost). Treating CKD must start from the stage of urinary abnormalities (or before). Thus, the window-of-opportunity is mostly in the hands of GPs, not nephrologists.

GlomCon

@GlomCon

5 years

Use of ACE inhibitors delays progression of kidney disease in patients with Alport syndrome By Dr Rheault @rheault_m #glomcon

1

15

40

0

18

42

Hans-Joachim Anders

@hjanders_hans

3 months

Now online in @NDTsocial The effect of preeclampsia on long-term kidney function among pregnant women with CKD 🧐Preeclampsia = greater risk of long-term CKD progression or ESKD , especially in patients with early-onset preeclampsia. ▶️

0

8

41

Hans-Joachim Anders

@hjanders_hans

8 months

Now open access in @NDTsocial IgA nephropathy: gut microbiome regulates the production of hypoglycosilated IgA1via the TLR4 signaling pathway ▶️

1

15

41

Hans-Joachim Anders

@hjanders_hans

4 years

How hyperuricemia with or without UA crystalluria affects the kidney. Mechanisms explaining #PERL #CKDFIX For next CKD allopurinol trial include only pts with UA crystalluria! @StefanieSteige6 @JASN_News Now online in JASN

0

13

40

Hans-Joachim Anders

@hjanders_hans

1 year

▶️Kidneys do not like smoking ☠️ Cumulative smoking dose is associated with subclinical renal injury

Cumulative smoking dose is associated with subclinical renal injury: a pathological study in...

ABSTRACTBackground. Epidemiological studies have identified smoking as an independent risk factor for development of chronic kidney disease. However, the e

academic.oup.com

1

11

40